Abstract

Objective: To analyze trends in screening and invasive prenatal diagnosis of chromosome abnormalities (CA) over a 13-year period and correlate them to changes in the national prenatal screening policy. Methods: We retrospectively reviewed Down syndrome (DS) screening tests and fetal karyotypes obtained by prenatal invasive testing (IT) in our fetal medicine unit between January 1999 and December 2011. Results: A total of 24,226 prenatal screening tests for DS and 11,045 invasive procedures have been analyzed. Over a 13-year period, utilization of non-invasive screening methods has significantly increased from 57% to 89%. The percentage of invasive procedures has declined from 49% to 12%, although the percentage of IT performed for maternal anxiety has increased from 22% to 55%. The percentage of detected CA increased from 2.5% to 5.9%. Overall, 31 invasive procedures are needed to diagnose 1 abnormal case, being 23 procedures in medical indications and 241 procedures in non-medical indications. Conclusions: Our experience on screening and invasive prenatal diagnostic practice shows a decrease of the number of IT, with a parallel decline in medical indications. There is an increasing efficiency of prenatal screening program to detect CA. Despite the increasing screening policies, our population shows a growing request for prenatal IT. The a priori low risk population shows a not negligible residual risk for relevant CA. This observation challenges the current prenatal screening strategy focused on DS; showing that the residual risk is higher than the current cut-off used to indicate an invasive technique.

Highlights

  • Current strategies for prenatal diagnosis of chromosome abnormalities (CA) focus on the selection of high-risk pregnancies, to perform invasive diagnostic procedures

  • According to Spanish health policies, second trimester screening for Down syndrome (DS) was carried out during the first 4 years and first trimester combined screening from 2003 onwards, either in a one-step or two-step strategy

  • Over a 13-year period, utilization of non-invasive screening methods has significantly increased from 57% to 89% (p < 0.0001)

Read more

Summary

Introduction

Current strategies for prenatal diagnosis of chromosome abnormalities (CA) focus on the selection of high-risk pregnancies, to perform invasive diagnostic procedures. Advanced maternal age was the main risk factor for Down syndrome (DS) and prenatal invasive procedure was routinely performed in women over 35 years [1,2]. This strategy only detects about half of DS cases, with many women undergoing an invasive procedure for each CA detected. First trimester prenatal screening has been developed; this includes maternal age, maternal serum concentration of free β-hCG and pregnancy-associated plasma protein (PAPP-A), combined with one ultrasound measurement, the nuchal translucency (NT). Implementation of early combined screening should enable to identify up to

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call